Agenus Inc. (NASDAQ:AGEN) has been given a $5.00 price objective by analysts at HC Wainwright in a report issued on Thursday. The firm presently has a “hold” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 18.34% from the company’s current price.
AGEN has been the subject of a number of other reports. JMP Securities reissued a “buy” rating on shares of Agenus in a research report on Thursday, December 1st. Zacks Investment Research downgraded Agenus from a “hold” rating to a “sell” rating in a research report on Tuesday, December 27th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $7.00 target price on shares of Agenus in a research report on Thursday, October 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $9.80.
Agenus (NASDAQ:AGEN) traded up 5.44% during trading on Thursday, hitting $4.46. 1,212,154 shares of the stock traded hands. Agenus has a 12 month low of $2.65 and a 12 month high of $7.49. The company’s 50 day moving average price is $4.04 and its 200 day moving average price is $5.20. The company’s market cap is $388.58 million.
This piece of content was first reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at http://www.wkrb13.com/markets/1981691/agenus-inc-agen-given-a-5-00-price-target-at-hc-wainwright.html.
In other Agenus news, major shareholder Corp Incyte bought 10,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 14th. The stock was purchased at an average price of $6.00 per share, for a total transaction of $60,000,000.00. Following the completion of the purchase, the insider now directly owns 17,763,968 shares in the company, valued at $106,583,808. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 7.60% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the company. RTW Investments LP raised its position in Agenus by 1.7% in the fourth quarter. RTW Investments LP now owns 4,210,264 shares of the company’s stock valued at $17,346,000 after buying an additional 68,620 shares during the period. RTW Investments LLC raised its position in Agenus by 70.5% in the third quarter. RTW Investments LLC now owns 4,141,644 shares of the company’s stock valued at $29,737,000 after buying an additional 1,712,495 shares during the period. State Street Corp raised its position in Agenus by 64.3% in the fourth quarter. State Street Corp now owns 3,502,274 shares of the company’s stock valued at $14,430,000 after buying an additional 1,370,515 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Agenus by 0.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 990,738 shares of the company’s stock valued at $7,113,000 after buying an additional 6,814 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its position in Agenus by 13.1% in the third quarter. Candriam Luxembourg S.C.A. now owns 517,700 shares of the company’s stock valued at $3,717,000 after buying an additional 60,000 shares during the period. Hedge funds and other institutional investors own 45.40% of the company’s stock.
Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/1981691/agenus-inc-agen-given-a-5-00-price-target-at-hc-wainwright.html
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.